{
	"add": {
		"doc": {
			"id": "9734deef563cf90be113b63cbb35652e5b917809315f02a5ea4c4ef288eafd2b",
			"url": "https://upload.wikimedia.org/wikipedia/commons/thumb/7/71/Haloperidol.svg/300px-Haloperidol.svg.png",
			"previous": " ",
			"after": " There has been extensive research into metallopharmaceuticals 53 54 including discussion of rhodium compounds in medicine 18 A substantial body of research has examined using metallocene derivatives of ruthenium 55 and iron 56 as metallopharmaceuticals One area of such research has utilised metallocenes in place of the fluorophenyl group in haloperidol 19 which is a pharmaceutical classified as a typical antipsychotic The ferrocenyl haloperidol compound investigated has structure C5H5 Fe C5H4 C O CH2 3 N CH2CH2 2C OH C6H4Cl and can be converted to the ruthenium analog via a transmetalation reaction Using the radioactive isotope 103Ru produces a ruthenocenyl haloperidol radiopharmaceutical with a high affinity for lung but not brain tissue in mice and rats 19 Beta decay of 103Ru produces the metastable isotope 103mRh in a rhodocenyl haloperidol compound This compound like other rhodocene derivatives has an unstable 19 valence electron configuration and rapidly oxidises to the expected cationic rhodocenium haloperidol species 19 The separation of the ruthenocenyl haloperidol and the rhodocenium haloperidol species and the distributions of each amongst bodily organs has been studied 20 103mRh has a half life of 56 min and emits a gamma ray of energy 39 8 keV so the gamma decay of the rhodium isotope should follow soon after the beta decay of the ruthenium isotope Beta and gamma emitting radionuclides used medically include 131I 59Fe and 47Ca and 103mRh has been proposed for use in radiotherapy for small tumours 18 ",
			"color": "white|0.092479 smoke|0.092479 snow|0.091587 ghost|0.091559 white|0.091559 white|0.091269 alice|0.091211 blue|0.091211 sea|0.09097 shell|0.09097 mint|0.090773 cream|0.090773 floral|0.089977 white|0.089977 azure|0.089778 lavender|0.088257 blush|0.088257 gray|0.020404 grey|0.020404 dim|0.01855 gray|0.01855 dim|0.01855 grey|0.01855 dark|0.017574 gray|0.017574 dark|0.017574 grey|0.017574 silver|0.012099 light|0.0088926 gray|0.0088926 light|0.0088926 grey|0.0088926 gainsboro|0.0079133 ivory|0.0027885  ",
			"after_weights": " There|1 has|0.99583 been|0.99167 extensive|0.9875 research|0.98333 into|0.97917 metallopharmaceuticals|0.975 53|0.97083 54|0.96667 including|0.9625 discussion|0.95833 of|0.95417 rhodium|0.95 compounds|0.94583 in|0.94167 medicine|0.9375 18|0.93333 A|0.92917 substantial|0.925 body|0.92083 of|0.91667 research|0.9125 has|0.90833 examined|0.90417 using|0.9 metallocene|0.89583 derivatives|0.89167 of|0.8875 ruthenium|0.88333 55|0.87917 and|0.875 iron|0.87083 56|0.86667 as|0.8625 metallopharmaceuticals|0.85833 One|0.85417 area|0.85 of|0.84583 such|0.84167 research|0.8375 has|0.83333 utilised|0.82917 metallocenes|0.825 in|0.82083 place|0.81667 of|0.8125 the|0.80833 fluorophenyl|0.80417 group|0.8 in|0.79583 haloperidol|0.79167 19|0.7875 which|0.78333 is|0.77917 a|0.775 pharmaceutical|0.77083 classified|0.76667 as|0.7625 a|0.75833 typical|0.75417 antipsychotic|0.75 The|0.74583 ferrocenyl|0.74167 haloperidol|0.7375 compound|0.73333 investigated|0.72917 has|0.725 structure|0.72083 C5H5|0.71667 Fe|0.7125 C5H4|0.70833 C|0.70417 O|0.7 CH2|0.69583 3|0.69167 N|0.6875 CH2CH2|0.68333 2C|0.67917 OH|0.675 C6H4Cl|0.67083 and|0.66667 can|0.6625 be|0.65833 converted|0.65417 to|0.65 the|0.64583 ruthenium|0.64167 analog|0.6375 via|0.63333 a|0.62917 transmetalation|0.625 reaction|0.62083 Using|0.61667 the|0.6125 radioactive|0.60833 isotope|0.60417 103Ru|0.6 produces|0.59583 a|0.59167 ruthenocenyl|0.5875 haloperidol|0.58333 radiopharmaceutical|0.57917 with|0.575 a|0.57083 high|0.56667 affinity|0.5625 for|0.55833 lung|0.55417 but|0.55 not|0.54583 brain|0.54167 tissue|0.5375 in|0.53333 mice|0.52917 and|0.525 rats|0.52083 19|0.51667 Beta|0.5125 decay|0.50833 of|0.50417 103Ru|0.5 produces|0.49583 the|0.49167 metastable|0.4875 isotope|0.48333 103mRh|0.47917 in|0.475 a|0.47083 rhodocenyl|0.46667 haloperidol|0.4625 compound|0.45833 This|0.45417 compound|0.45 like|0.44583 other|0.44167 rhodocene|0.4375 derivatives|0.43333 has|0.42917 an|0.425 unstable|0.42083 19|0.41667 valence|0.4125 electron|0.40833 configuration|0.40417 and|0.4 rapidly|0.39583 oxidises|0.39167 to|0.3875 the|0.38333 expected|0.37917 cationic|0.375 rhodocenium|0.37083 haloperidol|0.36667 species|0.3625 19|0.35833 The|0.35417 separation|0.35 of|0.34583 the|0.34167 ruthenocenyl|0.3375 haloperidol|0.33333 and|0.32917 the|0.325 rhodocenium|0.32083 haloperidol|0.31667 species|0.3125 and|0.30833 the|0.30417 distributions|0.3 of|0.29583 each|0.29167 amongst|0.2875 bodily|0.28333 organs|0.27917 has|0.275 been|0.27083 studied|0.26667 20|0.2625 103mRh|0.25833 has|0.25417 a|0.25 half|0.24583 life|0.24167 of|0.2375 56|0.23333 min|0.22917 and|0.225 emits|0.22083 a|0.21667 gamma|0.2125 ray|0.20833 of|0.20417 energy|0.2 39|0.19583 8|0.19167 keV|0.1875 so|0.18333 the|0.17917 gamma|0.175 decay|0.17083 of|0.16667 the|0.1625 rhodium|0.15833 isotope|0.15417 should|0.15 follow|0.14583 soon|0.14167 after|0.1375 the|0.13333 beta|0.12917 decay|0.125 of|0.12083 the|0.11667 ruthenium|0.1125 isotope|0.10833 Beta|0.10417 and|0.1 gamma|0.095833 emitting|0.091667 radionuclides|0.0875 used|0.083333 medically|0.079167 include|0.075 131I|0.070833 59Fe|0.066667 and|0.0625 47Ca|0.058333 and|0.054167 103mRh|0.05 has|0.045833 been|0.041667 proposed|0.0375 for|0.033333 use|0.029167 in|0.025 radiotherapy|0.020833 for|0.016667 small|0.0125 tumours|0.0083333 18|0.0041667 |0",
			"previous_weights": " "
		}
	}
}
